Northeast Investment Management Sells 150,086 Shares of Gilead Sciences, Inc. (GILD)

Northeast Investment Management lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 90.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,454 shares of the biopharmaceutical company’s stock after selling 150,086 shares during the period. Northeast Investment Management’s holdings in Gilead Sciences were worth $1,165,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Parnassus Investments CA grew its position in shares of Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the last quarter. Pioneer Investment Management Inc. grew its position in shares of Gilead Sciences by 84.0% in the 2nd quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock valued at $247,245,000 after buying an additional 1,595,085 shares during the last quarter. Harbour Capital Advisors LLC grew its position in shares of Gilead Sciences by 6,595.9% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,221,804 shares of the biopharmaceutical company’s stock valued at $17,262,000 after buying an additional 1,203,557 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Gilead Sciences by 75.0% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after buying an additional 1,092,206 shares during the last quarter. 73.97% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Northeast Investment Management Sells 150,086 Shares of Gilead Sciences, Inc. (GILD)” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://ledgergazette.com/2017/10/22/northeast-investment-management-sells-150086-shares-of-gilead-sciences-inc-gild.html.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the sale, the executive vice president now owns 113,237 shares of the company’s stock, valued at $8,945,723. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 446,819 shares of company stock valued at $36,338,919. Company insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) opened at 81.21 on Friday. The stock has a market capitalization of $106.05 billion, a P/E ratio of 8.82 and a beta of 1.14. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The firm has a 50-day moving average price of $82.63 and a 200-day moving average price of $72.65.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.08 EPS. On average, analysts predict that Gilead Sciences, Inc. will post $8.74 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

A number of equities research analysts have commented on GILD shares. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Thursday, August 31st. Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 price target on shares of Gilead Sciences in a research report on Thursday, August 31st. Credit Suisse Group reiterated an “outperform” rating and issued a $85.00 price target (up previously from $79.00) on

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Parnassus Investments CA grew its position in shares of Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the last quarter. Pioneer Investment Management Inc. grew its position in shares of Gilead Sciences by 84.0% in the 2nd quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock valued at $247,245,000 after buying an additional 1,595,085 shares during the last quarter. Harbour Capital Advisors LLC grew its position in shares of Gilead Sciences by 6,595.9% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,221,804 shares of the biopharmaceutical company’s stock valued at $17,262,000 after buying an additional 1,203,557 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Gilead Sciences by 75.0% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after buying an additional 1,092,206 shares during the last quarter. 73.97% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Northeast Investment Management Sells 150,086 Shares of Gilead Sciences, Inc. (GILD)” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://ledgergazette.com/2017/10/22/northeast-investment-management-sells-150086-shares-of-gilead-sciences-inc-gild.html.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the sale, the executive vice president now owns 113,237 shares of the company’s stock, valued at $8,945,723. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 446,819 shares of company stock valued at $36,338,919. Company insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) opened at 81.21 on Friday. The stock has a market capitalization of $106.05 billion, a P/E ratio of 8.82 and a beta of 1.14. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The firm has a 50-day moving average price of $82.63 and a 200-day moving average price of $72.65.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.08 EPS. On average, analysts predict that Gilead Sciences, Inc. will post $8.74 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

A number of equities research analysts have commented on GILD shares. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Thursday, August 31st. Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 price target on shares of Gilead Sciences in a research report on Thursday, August 31st. Credit Suisse Group reiterated an “outperform” rating and issued a $85.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research report on Tuesday, August 29th. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price target on the stock in a research report on Monday, June 26th. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $85.64.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply